Foghorn Therapeutics (FHTX) vs Genelux (GNLX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Genelux (GNLX) has outperformed Foghorn Therapeutics (FHTX) over the past year, losing 56.3% versus a loss of 62.8%. Genelux is the larger company by market cap ($103.4 million vs $103.1 million), about 1.0 times the size, while Foghorn Therapeutics is growing revenue faster (+36.8% vs +0.0%). Foghorn Therapeutics converts more of its revenue into profit, with a net margin of -240.3% versus -401812.5%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | FHTX | GNLX |
|---|---|---|
| Share price | $1.72 | $2.17 |
| Market cap | $103.14M | $103.36M |
| 1-day change | -3.37% | -4.82% |
| YTD return | -68.15% | -50.23% |
| 1-year return | -62.77% | -56.25% |
| 5-year return | -87.36% | — |
| P/E ratio (TTM) | 19.11 | — |
| EPS (TTM) | $0.09 | $-0.88 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $30.91M | $8.00K |
| Revenue growth (YoY) | +36.75% | 0.00% |
| Net income (latest FY) | $-74.28M | $-32.15M |
| Operating margin | -279.49% | -415175.00% |
| Net margin | -240.33% | -401812.50% |
| 52-week high | $7.61 | $5.89 |
| 52-week low | $1.66 | $1.77 |
| Distance from 52-week high | -77.40% | -63.16% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +142.44% | +767.74% |
| Average volume | 843.73K | 333.31K |
| Shares outstanding | 59.96M | 47.63M |
| Employees | 106 | 25 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Foghorn Therapeutics is more profitable, keeping -240.3 cents of every revenue dollar as net income versus -401812.5 cents for Genelux.
- Foghorn Therapeutics grew revenue faster in its latest fiscal year (+36.75% vs 0.00%).
About Foghorn Therapeutics
FHTX stock →Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system.
Health Care · Biotechnology: Pharmaceutical Preparations · 106 employees
About Genelux
GNLX stock →Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec (olvimulogene nanivacirepvec), a proprietary modified strain of the vaccinia virus indicated for the treatment of ovarian cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 25 employees
FHTX vs GNLX FAQ
Which is bigger, Foghorn Therapeutics or Genelux?
Genelux (GNLX) is larger, with a market capitalization of $103.36M compared with $103.14M for Foghorn Therapeutics (FHTX).
Which stock has performed better over the past year, FHTX or GNLX?
GNLX returned -56.25% over the past 12 months, compared with -62.77% for FHTX (price return, excluding dividends). Past performance does not predict future results.
Are Foghorn Therapeutics and Genelux in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.